Synovics Pharmaceuticals Stock Performance
| SYVC Stock | USD 0.0001 0.00 0.00% |
The entity has a beta of 0.0, which indicates not very significant fluctuations relative to the market. the returns on MARKET and Synovics Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Synovics Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of rather sound basic indicators, Synovics Pharmaceuticals is not utilizing all of its potentials. The current stock price tumult, may contribute to shorter-term losses for the shareholders. ...more
Last Split Factor 1:5 | Last Split Date 2001-05-30 |
1 | Joby, Archer Aviation Stocks Take Off After Cryptic Tweet From Tesla - Barrons | 10/06/2025 |
2 | Stock Market Today Stock-Market Rebound Evaporates as AI Fears Resurface - The Wall Street Journal | 11/20/2025 |
3 | Pound Rising Ahead of Crucial UK Budget - Bloomberg.com | 11/26/2025 |
Synovics Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Synovics Pharmaceuticals on September 29, 2025 and sell it today you would earn a total of 0.00 from holding Synovics Pharmaceuticals or generate 0.0% return on investment over 90 days. Synovics Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Synovics, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Synovics Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Synovics Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Synovics Pharmaceuticals, and traders can use it to determine the average amount a Synovics Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| SYVC |
Based on monthly moving average Synovics Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Synovics Pharmaceuticals by adding Synovics Pharmaceuticals to a well-diversified portfolio.
Synovics Pharmaceuticals Fundamentals Growth
Synovics Stock prices reflect investors' perceptions of the future prospects and financial health of Synovics Pharmaceuticals, and Synovics Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Synovics Stock performance.
| Return On Equity | -3.14 | ||||
| Return On Asset | -0.13 | ||||
| Profit Margin | (0.26) % | ||||
| Operating Margin | (1.18) % | ||||
| Current Valuation | 894.82 K | ||||
| Shares Outstanding | 29.83 M | ||||
| Price To Sales | 0.03 X | ||||
| Revenue | 25.96 M | ||||
| Gross Profit | 4.47 M | ||||
| EBITDA | (3.64 M) | ||||
| Net Income | (4.01 M) | ||||
| Cash And Equivalents | 129.86 K | ||||
| Total Debt | 2.1 M | ||||
| Current Ratio | 0.27 X | ||||
| Book Value Per Share | (0.06) X | ||||
| Cash Flow From Operations | 3.86 M | ||||
| Market Capitalization | 542.86 K | ||||
| Total Asset | 22.35 M | ||||
| Retained Earnings | (78.65 M) | ||||
| Working Capital | (12.87 M) | ||||
| Current Asset | 4.68 M | ||||
| Current Liabilities | 17.55 M | ||||
About Synovics Pharmaceuticals Performance
By analyzing Synovics Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Synovics Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Synovics Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Synovics Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 56.11 | 53.30 | |
| Return On Tangible Assets | (0.44) | (0.46) | |
| Return On Capital Employed | (0.25) | (0.24) | |
| Return On Assets | (0.16) | (0.17) | |
| Return On Equity | (0.72) | (0.76) |
Things to note about Synovics Pharmaceuticals performance evaluation
Checking the ongoing alerts about Synovics Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Synovics Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Synovics Pharmaceuticals generated a negative expected return over the last 90 days | |
| Synovics Pharmaceuticals has some characteristics of a very speculative penny stock | |
| Synovics Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Synovics Pharmaceuticals currently holds 2.1 M in liabilities. Synovics Pharmaceuticals has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Synovics Pharmaceuticals' use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 25.96 M. Net Loss for the year was (4.01 M) with profit before overhead, payroll, taxes, and interest of 4.47 M. |
- Analyzing Synovics Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Synovics Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Synovics Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Synovics Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Synovics Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Synovics Pharmaceuticals' stock. These opinions can provide insight into Synovics Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Synovics Stock analysis
When running Synovics Pharmaceuticals' price analysis, check to measure Synovics Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Synovics Pharmaceuticals is operating at the current time. Most of Synovics Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Synovics Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Synovics Pharmaceuticals' price. Additionally, you may evaluate how the addition of Synovics Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital |